Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06851858 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Study acronym: ARAY
StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Primary and study completion dates changed from estimate of May 27, 2026 to May 26, 2026 · Eligibility criteria expanded, about 11 words Show 2 more changesShow less
    • Primary and study completion dates changed from estimate of May 27, 2026 to May 26, 2026
    • Eligibility criteria expanded, about 11 words
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 64 to confirmed 69 · Primary and study completion dates: Jul 8, 2026 to May 27, 2026 · Site details revised at 18 of 18 sitesv7 Show 3 more changesShow less
    • Enrollment target: estimated 64 to confirmed 69
    • Primary and study completion dates: Jul 8, 2026 to May 27, 2026
    • Site details revised at 18 of 18 sites
  3. Primary and study completion dates: Feb 16, 2026 to Jul 8, 2026v6
  4. Study sites: 17 to 18v5
  5. Study sites: 16 to 17 Primary and study completion dates: Jan 27, 2026 to Feb 16, 2026 · Eligibility criteria revisedv4 Show 2 more changesShow less
    • Primary and study completion dates: Jan 27, 2026 to Feb 16, 2026
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

Show 2 earlier versionsHide 2 earlier versions
  1. Site details revised at 2 of 16 sitesv3
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 14 to 16 · Primary and study completion dates: Jan 9, 2026 to Jan 27, 2026 · Start date changed from estimate of Feb 21, 2025 to Mar 12, 2025v2 Show 3 more changesShow less
    • Study sites: 14 to 16
    • Primary and study completion dates: Jan 9, 2026 to Jan 27, 2026
    • Start date changed from estimate of Feb 21, 2025 to Mar 12, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Diabetes
4,286 trials monitored
See 187 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
Type 2 Diabetes
2,100 trials monitored
See 102 trials at risk
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Trial Details
NCT Number NCT06851858
Lead Sponsor AstraZeneca
Conditions Endocrinology, Diabetes, Type II, Obesity
Enrollment 69 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov